<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35830032</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-4219</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Arquivos de gastroenterologia</Title><ISOAbbreviation>Arq Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>225</EndPage><MedlinePgn>219-225</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S0004-2803.202202000-40</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0004-28032022000200219</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Proton pump inhibitors (PPIs) are one of the most prescribed drugs in the world. Frequent use and long-term maintenance of these drugs drew the attention of researchers for sporadic adverse effects reports.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this narrative review is to discuss appropriate data and causality related to these adverse events and PPIs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A narrative review was conducted by systematizing information about safety and adverse events on PPIs from 2015 to 2020. A structured search on Pubmed was performed to identify systematic reviews and meta-analysis investigating the following situations: a) gastric cancer; b) micronutrients deficiency; c) acid rebound; d) infections; e) fractures; f) dementia; g) kidney disease; and h) sudden death and cardiovascular changes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Recent studies have potentially associated PPIs with some adverse events as osteoporosis-related fractures. There are also reports of intestinal infections, including Clostridium difficile, besides poor vitamins absorption and minerals such as vitamin B12, magnesium, and iron. Furthermore, there are some dementia, pneumonia, kidney disease, myocardial infarction, and stroke reports. For kidney diseases, studies consistently suggest that the use of PPI may be associated with an increased risk of adverse kidney events, especially in the elderly, with long-term PPI use and pre-existing kidney disease. Another additional question is whether chronic PPI use would also lead to the onset of gastric cancer. The abrupt discontinuation of PPIs is also related to increased gastric acid production above pre-PPI treatment levels; this phenomenon is called acid rebound.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The key to mitigate adverse effects is the rational use of PPIs at the lowest effective dose and in the shortest possible duration. Although these adverse effects have a potential clinical impact, their causal association is still subject to validation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chinzon</LastName><ForeName>Decio</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3030-6687</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina da Universidade de S&#xe3;o Paulo, Departamento de Gastroenterologia, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domingues</LastName><ForeName>Gerson</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0431-451X</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina da Universidade do Estado do Rio Janeiro, Departamento de Gastroenterologia, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosetto</LastName><ForeName>Nivia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0389-4156</Identifier><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrotti</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4842-1552</Identifier><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Gastroenterol</MedlineTA><NlmUniqueID>15310600R</NlmUniqueID><ISSNLinking>0004-2803</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="Y">Kidney Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="Y">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>13</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35830032</ArticleId><ArticleId IdType="doi">10.1590/S0004-2803.202202000-40</ArticleId><ArticleId IdType="pii">S0004-28032022000200219</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>